Arbutus Biopharma Corporation
ABUS
$3.59
$0.010.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 112.74% | -37.21% | 35.11% | 1.92% | -15.81% |
| Total Depreciation and Amortization | -96.91% | -7.04% | -7.24% | -8.94% | 4.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.97% | 410.70% | 1,114.37% | -14.18% | 81.95% |
| Change in Net Operating Assets | -761.35% | 284.30% | -115.40% | 26.11% | 168.88% |
| Cash from Operations | -8.58% | 30.60% | 40.35% | 4.81% | 25.84% |
| Capital Expenditure | -- | -- | -- | 100.00% | 99.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 58.72% | -3.73% | -39.27% | -214.80% | 327.39% |
| Cash from Investing | 58.83% | -2.95% | -39.66% | -214.93% | 582.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.14% | -88.60% | -62.67% | 5.59% | 413.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.14% | -88.60% | -62.67% | 5.59% | 413.92% |
| Foreign Exchange rate Adjustments | 362.50% | 130.77% | -335.71% | -37.50% | -700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.29% | -95.56% | -48.78% | -220.11% | 247.17% |